Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease
- 1 October 2004
- journal article
- Published by Elsevier in Clinical Immunology
- Vol. 113 (1), 47-55
- https://doi.org/10.1016/j.clim.2004.05.004
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Indoleamine 2,3-dioxygenase (IDO) expression in invasive extravillous trophoblast supports role of the enzyme for materno-fetal toleranceJournal of Reproductive Immunology, 2004
- Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenaseNature Medicine, 2003
- Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s diseaseGastroenterology, 2003
- T cell apoptosis by tryptophan catabolismCell Death & Differentiation, 2002
- The role of Th1/Th2 polarization in mucosal immunityNature Medicine, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-γ-independent mechanismEuropean Journal of Immunology, 2001
- Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileumGastroenterology, 1998
- Control of Extracellular Matrix Degradation by Interferon-γPublished by Springer Nature ,1996
- Medical therapy of ulcerative colitisThe Lancet, 1993